Overall Status

Recruiting (26)

Not yet recruiting (17)

Active, not recruiting (3)

Completed (2)

Withdrawn (2)

Available (1)

Enrolling by invitation (1)

Terminated (1)

Phase

phase 2 (21)

phase 3 (7)

phase 1 (5)

phase 1/phase 2 (4)

phase 2/phase 3 (2)

phase 4 (1)

Study Documents

Intervention Type

drug (41)

biological (9)

other (3)

procedure (1)

Funder Type

Other (28)

Industry (23)

NIH (2)

Study Type

Interventional (40)

Observational (10)

Observational [Patient Registry] (2)

Expanded Access (1)

BTKi

Showing 51 - 53 of 53

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Relapsed/Refractory Mantle Cell Lymphoma Trial in Worldwide (brexucabtagene autoleucel, Cyclophosphamide, Fludarabine)

Active, not recruiting

Has Results

Relapsed/Refractory Mantle Cell Lymphoma

brexucabtagene autoleucel
+3 more

Gilbert, Arizona
+31 more

Jan 26, 2023

Mantle Cell Lymphoma Trial in Guangzhou (R-CHOP/R-DHAOx; Zanubrutib(induction); ASCT conditioning ; Zanubrutinib(Maintenance))

Recruiting

Mantle Cell Lymphoma

R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）

Guangzhou, Guangdong, China

Department of Medical Oncology, Sun Yat-sen University Cancer Ce

Aug 24, 2021

FLT3-ITD Mutation, Acute Myeloid Leukemia, Brutons Tyrosine Kinase Trial in Guangzhou (Ibrutinib)

Enrolling by invitation

FLT3-ITD Mutation
+2 more

Ibrutinib

Guangzhou, Guangdong, China

Department of Hematology,Nanfang Hospital, Southern Medical Univ

Aug 20, 2018